GSK plc (NYSE:GSK) Shares Sold by XTX Topco Ltd

XTX Topco Ltd decreased its holdings in shares of GSK plc (NYSE:GSK) by 85.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,140 shares of the pharmaceutical company’s stock after selling 41,185 shares during the period. XTX Topco Ltd’s holdings in GSK were worth $241,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Dorsey & Whitney Trust CO LLC boosted its holdings in GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock worth $389,000 after buying an additional 278 shares in the last quarter. GC Wealth Management RIA LLC raised its position in shares of GSK by 2.6% during the fourth quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock worth $474,000 after purchasing an additional 353 shares during the period. Jacobi Capital Management LLC lifted its holdings in shares of GSK by 3.9% during the fourth quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock valued at $352,000 after purchasing an additional 389 shares during the last quarter. Gladstone Institutional Advisory LLC lifted its holdings in shares of GSK by 3.4% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company’s stock valued at $413,000 after purchasing an additional 407 shares during the last quarter. Finally, CENTRAL TRUST Co increased its stake in GSK by 5.6% in the 4th quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company’s stock worth $262,000 after purchasing an additional 414 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

GSK has been the topic of a number of recent analyst reports. Morgan Stanley started coverage on shares of GSK in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. BNP Paribas assumed coverage on shares of GSK in a research note on Tuesday, April 15th. They set a “neutral” rating and a $35.25 target price on the stock. Finally, StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday. Eight equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $40.58.

GSK Stock Performance

NYSE:GSK opened at $37.42 on Friday. The firm has a market capitalization of $77.21 billion, a PE ratio of 23.53, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.93. The firm has a 50-day moving average price of $37.50 and a 200 day moving average price of $36.02.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Research analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were given a dividend of $0.3932 per share. The ex-dividend date was Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.20%. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is presently 100.63%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.